系统性红斑狼疮中的抗线粒体抗体与肾炎、动脉血管事件及死亡率相关并可预测这些结局
该研究基于系统性红斑狼疮国际协作组(SLICC)起始队列1114例参与者,采用ELISA检测抗全线粒体(AwMA)、抗线粒体DNA(AmtDNA)和抗线粒体RNA(AmtRNA)抗体,并以多变量Cox回归分析其与肾炎、动脉血管事件(AVE)及死亡率的关系。结果显示,SLE患者各类AMA滴度均高于健康人,较高的AMA水平与肾炎风险升高相关(最近一次AmtDNA的aHR=1.61,95%CI 1.43-1.82;AmtRNA的aHR=1.59,95%CI 1.46-1.73),基线AwMA预测早期死亡(aHR=1.19,95%CI 1.02-1.40),最近一次AmtDNA与随访期间死亡风险升高相关(aHR=1.68,95%CI 1.28-2.19),且AmtRNA对AVE的影响在女性中更强。
要点
- SLE患者AwMA、AmtDNA、AmtRNA滴度均高于健康人。
- 较高AmtDNA与AmtRNA水平与肾炎风险升高相关。
- 基线AwMA预测早期死亡,最近一次AmtDNA与随访期死亡相关。
核心结论
- 基线和最近一次AMA水平评估可能有助于识别SLE中包括死亡在内的严重结局高风险个体。
研究设计与样本
- 研究纳入SLICC起始队列1114例参与者,检测血清AwMA、AmtDNA和AmtRNA,并采用多变量Cox回归分析其与结局的关联。
主要发现
- SLE患者所有AMA滴度均高于健康个体。
- 较高的AMA水平与肾炎风险升高相关,最近一次AmtDNA的aHR=1.61(95%CI 1.43-1.82,每增加1 SD),AmtRNA的aHR=1.59(95%CI 1.46-1.73)。
- 较高的基线AwMA水平预测早期死亡(aHR=1.19,95%CI 1.02-1.40)。
- 最近一次AmtDNA与整个随访期间死亡风险升高相关(aHR=1.68,95%CI 1.28-2.19)。
- 对于AVE,较高AmtRNA的影响在女性中更强。
临床怎么用
- 在SLE管理中可考虑检测AMA(AwMA、AmtDNA、AmtRNA)以辅助识别肾炎、AVE和死亡高风险患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Systemic lupus erythematosus (SLE) remains a deadly disease, yet our ability to predict adverse outcomes is poor. Mitochondria are organelles recognised by the immune system when released from cells, and antimitochondrial antibodies (AMA) can be detected in people with SLE. We assessed AMA as markers of nephritis, arterial vascular events (AVE), and other outcomes including mortality. METHODS: We studied sera and data from 1114 participants of the Systemic Lupus International Collaborating Clinics inception cohort. We measured antiwhole mitochondria (AwMA), antimitochondrial DNA (AmtDNA), and antimitochondrial RNA (AmtRNA) antibodies by direct Enzyme-Linked ImmunoSorbent Assays (ELISAs). Separate multivariable Cox proportional hazards regression models estimated associations of either baseline or most recent measures of AMA with the outcomes, adjusted for biological sex, age, medications, and other clinical factors. Interactions of AMA with biological sex were tested for each outcome. RESULTS: All AMA titres were elevated in SLE vs healthy individuals. Higher AMA levels were associated with a higher hazard of nephritis, with the strongest associations for most recent AmtDNA (adjusted hazard ratio [aHR] =1.61 for increase of 1 SD, 95% CI 1.43-1.82) and AmtRNA (aHR =1.59, 1.46-1.73). Higher baseline AwMA levels predicted early mortality (aHR =1.19, 1.02-1.40). Most recent AmtDNA (aHR =1.68, 1.28-2.19) was associated with higher mortality throughout the follow-up. For AVE, the impact of higher AmtRNA was stronger in females. CONCLUSIONS: Baseline and most recent assessments of AMA levels may help identify individuals at higher risk of severe outcomes in SLE, including mortality. Integrating AMA into precision medicine strategies will allow deeper exploration of lupus heterogeneity.
引用
- Becker YLC, Boilard É, Rollet-Labelle E, et al. Antimitochondrial antibodies in systemic lupus erythematosus are associated with and predict nephritis, arterial vascular events, and mortality. Ann Rheum Dis. 2025. PMID: 41390302. doi:10.1016/j.ard.2025.11.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。